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Abstract
Estrogens have long been known as important regulators of the female reproductive functions; however, our understanding of the role estrogens 
play in the human body has changed significantly over the past years. It is now commonly accepted that estrogens and androgens have important 
functions in both female and male physiology and pathology. This is in part due to the local synthesis and action of estrogens that broadens the role 
of estrogen signaling beyond that of the endocrine system. Furthermore, there are several different mechanisms through which the three estrogen 
receptors (ERs), ERα, ERβ and G protein-coupled estrogen receptor 1 (GPER1) are able to regulate target gene transcription. ERα and ERβ are mostly 
associated with the direct and indirect genomic signaling pathways that result in target gene expression. Membrane-bound GPER1 is on the other 
hand responsible for the rapid non-genomic actions of estrogens that activate various protein-kinase cascades. Estrogen signaling is also tightly 
connected with another important regulatory entity, i.e. epigenetic mechanisms. Posttranslational histone modifications, microRNAs (miRNAs) and 
DNA methylation have been shown to influence gene expression of ERs as well as being regulated by estrogen signaling. Moreover, several coregu-
lators of estrogen signaling also exhibit chromatin-modifying activities further underlining the importance of epigenetic mechanisms in estrogen 
signaling. This review wishes to highlight the newer aspects of estrogen signaling that exceed its classical endocrine regulatory role, especially emp-
hasizing its tight intertwinement with epigenetic mechanisms.
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Estrogens are perceived manly as ovarian sex hor-
mones responsible for cellular proliferation and 
growth of tissues related to reproduction. In pre-
menopausal women ovaries represent by far the 
most important source of circulating estrogens, al-
though during pregnancy, placenta also secrets 
significant amounts of estrogens into the circula-
tion (1). In addition to the effects on the female re-
productive functions, estrogens also play a signifi-
cant role in the regulation of skeletal homeostasis, 
lipid and carbohydrate metabolism, electrolyte 
balance, skin physiology, the cardiovascular sys-
tem and the central nervous system (1,2). Due to 
this wide regulatory role, it is not surprising that 
estrogens also have an important function in male 
physiology and cannot be viewed solely as female 
sex hormones. Postmenopausal women, due to 
the decline in their ovary function, and men are 
largely dependent on local synthesis of estrogens 
in extragonadal target tissues. This local produc-
tion of estrogens extends their signaling from en-
docrine to paracrine, autocrine and intracrine (3). 
The complexity is further increased by multiple 
mechanisms of estrogen signaling, namely the 
well established direct and indirect genomic sign-
aling, the fast non-genomic actions of steroid hor-
mones and ligand-independent signaling (4). 
Moreover, estrogen signaling is also tightly inter-
twined with epigenetic mechanisms which have 
been an important focus of research in recent 
years. Posttranslational histone modifications, mi-
croRNAs (miRNAs) and DNA methylation are im-
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portant regulators of gene expression acting both 
upstream and downstream from estrogen recep-
tors (ERs). Certain coregulators of estrogen signal-
ing are able to induce posttranslational changes to 
histone proteins and specific epigenetic changes 
are necessary for initiation of transcription. Fur-
thermore, different pathologies, aging and envi-
ronmental factors can potentially influence estro-
gen signaling and regulation through induction of 
epigenetic changes (5,6). This review wishes to 
highlight additional aspects of estrogen signaling 
that exceed the classical concept of endocrine reg-
ulation and particularly point out the close rela-
tionship between estrogen signaling and epige-
netic mechanisms.
Distribution of estrogen synthesis in the 
human organism
In addition to ovaries, several extragonadal tissues 
also produce estrogens. These include mesenchy-
mal cells of the adipose tissue including that of the 
breast, osteoblasts and chondrocytes, aortic 
smooth muscle cells and vascular endothelium, as 
well as numerous parts of the brain (7). In contrast 
to the importance of ovaries in premenopausal 
women, in postmenopausal women and men ex-
tragonadal tissues represent both the predomi-
nant source of estrogen synthesis and the main 
site of estrogen action. Only estrogens that escape 
local metabolism can enter the circulation, sug-
gesting that plasma levels of estrogens reflect 
rather than direct estrogen action in postmeno-
pausal women and men (7). This was confirmed by 
several studies comparing tissue and plasma sex 
steroid concentrations. They showed that in post-
menopausal women concentrations of estrogens 
in breast cancer and abdominal adipose tissue 
were several fold higher than in plasma (8-10). As a 
consequence, the levels of active steroid hormones 
in the circulation of postmenopausal women and 
men are probably of no significance in assessing 
their concentrations in individual extragonadal tis-
sues (7). Sex- and menopause-based differences in 
estrogen synthesis are summarized in Table 1.
In contrast to ovaries, estrogen production in ex-
tragonadal tissues is dependent on the availability 
of C19 steroid precursors, namely testosterone, an-
drostenedione, dehydroepiandrosterone (DHEA) 
and dehydroepiandrosterone sulfate (DHEAS). In 
target tissues, testosterone can be converted to ei-
ther 5α-dihydrotestosterone (DHT), the principal 
ligand for androgen receptors, or to 17β-estradiol, 
the most potent of the estrogens. Similarly, al-
though requiring several enzymatic reactions, DH-
EAS, DHEA and androstenedione can also be con-
verted to 17β-estradiol or DHT (Figure 1). Distribu-
tion of the required enzymes varies in different ex-
tragonadal tissues, making the metabolism of DH-
EAS and DHEA tissue-specific. In plasma of post-
menopausal women and men, DHEAS is by far the 
most abundant steroid precursor, followed by 













Plasma levels of 17β-estradiol 0.11-2.20 nM (depending on the phase of the cycle) around 0.04 nM around 0.10 nM
Intracrine formation of 17β-estradiol 
in extragonadal tissues estimated at around 75% estimated at around 100% estimated at around 100%
Source molecules for 17β-estradiol 
synthesis
blood-derived cholesterol 







DHEA – dehydroepiandrosterone; DHEAS – dehydroepiandrosterone sulphate.
Table 1. Summary of sex- and menopause-based differences in estrogen synthesis (1,4,7,11,76).
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DHEA. Concentrations of both are several orders 
of magnitude greater than those of the active sex 
steroids, although their secretion and plasma con-
centrations decline significantly with advancing 
age. Interestingly, in postmenopausal women 
even the concentration of circulating testosterone 
exceeds that of 17β-estradiol by an order of mag-
nitude. Approximately 25% of this testosterone is 
secreted directly from the ovaries, while the rest is 
formed in extragonadal tissues from steroid pre-
cursors. Androstenedione and DHEA are derived 
from both the adrenal cortex and the ovaries, 
whereas DHEAS is secreted entirely from the 
adrenals. The sheer amount of DHEAS and DHEA 
present in the circulation means they form a large 
reservoir of precursors available for the conversion 
to testosterone and estrogens in extragonadal tis-
sues. Since testosterone can be converted in one 
reaction to either a ligand active at androgen re-
ceptor or a ligand active at estrogen receptors, it 
can be viewed as a circulating pro-hormone. Simi-
lar to the importance of estrogens in male physiol-
ogy, high circulating concentrations of androgens 
indicate their significant role in women as well. In 
this light, it is impossible to separate estrogen sig-
naling from androgen signaling or give them gen-
der-specific roles. Therefore, it is always important 
to consider both regulatory pathways and their 
tight intertwinement in either women or men 
(3,7,11). This fact only further accentuates the cen-
tral role of extragonadal production of steroid hor-
mones, for a long time an overlooked aspect of es-
trogen signaling.
Structure and function of estrogen 
receptors
Estrogens exert their effects by binding to their 
designated receptors. In spite of the importance of 
estrogen signaling there are only three known re-
ceptors that mediate all of the estrogenś  effects. 
ERα was discovered first and is the most thorough-
ly investigated. Significantly homologues ERβ was 
identified almost four decades later and showed 
to have distinct, non-redundant roles (12). Another 
decade had to pass for the association of G pro-
tein-coupled estrogen receptor 1 (GPER1) with es-
trogen signaling. Characteristics of all three recep-
tors are summarized in Table 2.
ERα has at least three and ERβ at least five differ-
ent isoforms. Unlike the full length ERα, the two 
shorter ERα isoforms lack the N-terminal domain. 
Since they have the ability to heterodimerize with 
the full length ERα, they are able to repress ERα ac-
tivity. The shortest ERα isoform termed ERα36, also 
acts as a membrane located ER able to interact 
with GPER1. The four shorter ERβ isoforms differ 
from the full length ERβ mostly in their ligand-
binding domain, resulting in compromised ligand-
binding ability. ERβ isoforms that are unable to 
bind ligands or coactivators and have no transcrip-
tional activity dimerize preferentially with ERα, 
Figure 1. Schematic representation of estrogen synthesis in ex-
tragonadal tissues.
Estrogens and androgens are produced from C19 steroid precur-
sors through several enzymatic conversions. Testosterone can 
be converted to the most active ligand on the androgen recep-
tor, i.e. DHT, or the most active ligand on the estrogen receptor, 
i.e. 17β-estradiol, in a single reaction.
3β-HSD – 3β-hydroxysteroid dehydrogenase; 17β-HSD – 17β-
hydroxysteroid dehydrogenas; DHEA – dehydroepiandros-
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thereby silencing ERα signaling. This indicates that 
different ERα and ERβ isoforms can have a very di-
verse influence on estrogen signaling and target 
gene regulation (13,14). Furthermore, relative con-
centrations of ERα and ERβ in a given cell signifi-
cantly influence its response to various ligands. 
Homodimers of ERα and ERβ were shown to regu-
late largely different sets of genes from that of 
ERα/β heterodimers. This is supported by the ob-
servation of completely distinct cellular responses 
by ER subtype-specific and non-specific agonists. It 
was also suggested that ERβ exerts an inhibitory ef-
fect on ERα-mediated signaling. Slightly different, 
in some instances even opposite, roles of ERα and 
ERβ are additionally underscored by differences in 
their expression in various tissues and organs (2).
GPER1, a plasma membrane receptor formerly 
known as an orphan G protein-coupled receptor 
30 (GPR30), is genetically and structurally unrelat-
ed to ERα and ERβ. It is located on the cell surface 
and is responsible for rapid estrogen signaling, al-
though certain ERα and ERβ variants have also 
been associated with the plasma membrane and 
the non-genomic signaling (13,14). GPER1 func-
tions and is expressed independently from the 
two ERs. It has high affinity, limited capacity, dis-
placeable, single binding sites for estrogens. In 
comparison to nuclear ERs, its binding affinity for 
17β-estradiol is considerably lower and the rates 
of association and dissociation are very rapid and 
completed within a few minutes. It displays largely 
similar ligand binding specificities to those of the 
nuclear ERs with certain distinct differences. The 
specificity of GPER1 for estrogens is also under-
lined by the fact, that other steroid hormones pos-
sess very low binding affinities for this receptor 
(15-17).
Mechanisms of estrogen signaling
Estrogen dependent signaling can be roughly di-
vided into genomic and non-genomic, based on 
the outcome of cellular events, e.g. modulation of 
gene expression or activation of signaling cas-
cades, respectively. Furthermore, binding of the 
estrogen-ER complex to DNA can be either direct 
or indirect. Different mechanisms of estrogen sig-
naling are represented in Figure 2.
Direct genomic signaling
Direct genomic signaling pathway is considered as 
the classical mechanism of estrogen signaling. The 
binding of 17β-estradiol to ERα or ERβ in the cyto-
plasm of target cells causes conformational chang-
Receptor characteristic ERα ERβ GPER1
Receptor superfamily nuclear steroid hormone receptor superfamily G-protein coupled receptor superfamily
Type nuclear membrane-bound G protein-coupled
Structure DNA-binding domain,ligand-binding domain, N-terminal domain
7 transmembrane α-helical regions, 4 
extracellular and 4 cytosolic segments
Chromosome region 6q25.1 14q23.2 7p22.3
Number of isoforms 3 5 1
Size 595 aa 530 aa 375 aa
Distribution in human 
tissues
uterus, epididymis, 
breast, liver, kidney, white 
adipose tissue, prostate, 
ovary, testes, skeleton, 
brain
colon, salivary gland, 
vascular endothelium, 
lung, bladder, prostate, 
ovary, testes, skeleton, 
brain
central and peripheral nervous system, 
uterus, ovaries, mammary glands, testes, 
spermatogonial cells, gastrointestinal system, 
pancreas, kidney, liver, adrenal and pituitary 
glands, bone tissue, cardiovascular system, 
immune cells
Tamoxifen activity partial agonist antagonist agonist
ER – estrogen receptor; GPER1 – G protein-coupled estrogen receptor 1; aa – amino acids.
Table 2. Characteristics of estrogen receptors (2,12-15,17,18,77).
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Indirect genomic signaling
17β-estradiol can also influence expression of 
genes that do not harbour EREs in their promoter 
regions. In fact, around one third of the estrogen 
responsive genes lack ERE-like sequences. In the 
case of ERE-independent genomic signaling lig-
and-activated ERs do not bind DNA directly, but 
rather through protein-protein interactions with 
other classes of transcription factors at their re-
spective response elements. This mode of action 
enables activation or repression of target gene ex-
pression and significantly broadens estrogenś  
regulatory influence. One of the best described 
examples includes interaction of estrogen-ER com-
plex with FBJ murine osteosarcoma viral oncogene 
homolog (FOS) and jun proto-oncogene (JUN) 
proteins at the activator protein 1 (AP-1) binding 
sites in genes encoding ovalbumin, insulin-like 
growth factor 1 (IGF1), collagenase, cyclin D1 (CC-
ND1) and choline acetyltransferase. The result de-
pends on the ER subtype and type of the ligand. 
Other transcription factors that facilitate estrogen 
signaling also include Sp1 transcription factor, nu-
clear factor κB (NFκB), CCAAT/enhancer binding 
protein β (C/EBPβ), GATA binding protein 1 (GATA1) 
and signal transducer and activator of transcrip-
tion 5 (STAT5) (19).
Non-genomic signaling
It has been known for a long time that certain es-
trogen-induced changes are simply too rapid to 
be associated with target gene transcription and 
subsequent protein synthesis. Non-genomic ac-
tions are common to steroid hormones and are 
usually associated with the activation of various 
protein-kinase cascades that can eventually lead 
to indirect changes in gene expression due to 
phosphorylation of transcription factors. Non-ge-
nomic estrogen signaling is most often associated 
with a subset of membrane bound ER, e.g. GPER1 
and certain variants of ERα and ERβ. Binding of es-
trogens to ERs located at the cell surface can cause 
mobilization of intracellular calcium, stimulation of 
adenylate cyclase activity and cyclic adenosine 
monophosphate (cAMP) production, activation of 
the mitogen-activated protein kinase (MAPK) sign-
Figure 2. The representation of different mechanisms of estro-
gen signaling.
(I.) Direct genomic signaling pathway, considered the classical 
mechanism of estrogen signaling, promotes target gene ex-
pression by binding the E2-ER complex directly to the ERE. (II.) 
In the case of indirect genomic signaling pathway, E2-activated 
ERs bind DNA through protein-protein interactions with other 
classes of transcription factors at their respective response el-
ements. (III.) Non-genomic signaling pathway starts with the 
binding of E2 to the ERs located at the plasma membrane re-
sulting in the activation of various protein-kinase cascades. 
These can eventually lead to changes in gene expression due to 
phosphorylation of transcription factors. (IV). Ligand-indepen-
dent signaling pathway causes ER activation and target gene 
transcription through phosphorylation of ERs or their associ-
ated coregulators.
E2 – 17β-estradiol; ER – estrogen receptor; ERE – estrogen re-
sponse element; P – phosphate group; TF – transcription factor; 





















es that enable receptor dimerization, translocation 
to the nucleus and binding to the estrogen re-
sponse elements (EREs) located in or near the pro-
moters of target genes. Binding of the ligand to 
the receptor also triggers recruitment of a variety 
of coregulators in a complex that alters chromatin 
structure and facilitates recruitment of the RNA 
polymerase II transcriptional machinery. In this 
way, estrogen-ER complex acts as a transcriptional 
activator promoting gene expression (18).
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aling pathway, activation of the phosphoinositol 
3-kinase signaling pathway and activation of mem-
brane tyrosine kinase receptors (14,19). GPER1 is 
specifically associated with the stimulation of ade-
nylate cyclase and activation of EGFR (15). Molecu-
lar mechanisms underlying non-genomic estrogen 
signaling are without a doubt diverse and numer-
ous and may depend on a number of conditions, 
like the availability of signal transduction mole-
cules and downstream targets, suggesting a cell 
type-specific mechanism.
Ligand-independent signaling
In addition to genomic and non-genomic ligand-
dependent estrogen signaling, ERs can also be ac-
tivated in the absence of 17β-estradiol or another 
suitable ligand. Phosphorylation of the receptors 
on certain residues or their associated coregula-
tors can cause ligand-independent ER activation. 
The two most often targeted amino acids are ser-
ine and tyrosine. Signaling pathways responsible 
for this modulation include regulators of general 
cellular phosphorylation state, such as protein ki-
nase A (PKA) or protein kinase C (PKC), extracellu-
lar signals such as peptide growth factors, cy-
tokines or neurotransmitters and cell cycle regula-
tors. Peptide growth factors represent especially 
important group of estrogen-independent ER ac-
tivators that include epidermal growth factor 
(EGF), insulin, IGF1 and transforming growth factor 
β (TGFβ). Principle intermediates between growth 
factors and ERs are the guanine nucleotide-bind-
ing protein p21ras and MAPK phosphorylation cas-
cades, among others. Additional extracellular sig-
nals that modulate ER activity include heregulin, 
interleukin 2 and dopamine, as well as regulatory 
proteins cyclin A and D1 (12).
It has become clear that the classic genomic mech-
anism contributes only a small part to the com-
plexity of estrogen signaling. It is expected that 
17β-estradiol is able to regulate expression of the 
same target gene through multiple mechanisms, 
both genomic and non-genomic. In addition, the 
same promoter sequence can harbour both ERE as 
well as response elements associated with other 
transcription factors. The final gene response 
therefore depends on multiple factors including 
combination of transcription factors present on 
the gene promoter, expression levels and cellular 
localization of all three ERs, their numerous coreg-
ulators, and signaling components, as well as the 
nature of the stimuli. Since these variables can dif-
fer significantly among various cell types, it is pos-
sible that estrogens use distinct signaling path-
ways depending on the cellular context and in this 
way ensure very precise and cell-specific regula-
tion of target gene expression.
Interactions of epigenetic mechanisms 
and estrogen signaling
Estrogen signaling controls several physiological 
processes by directly and indirectly regulating tar-
get gene transcription. Another group of impor-
tant gene expression regulators receiving a lot of 
attention in recent years consists of epigenetic 
mechanisms. These include posttranslational his-
tone modifications, miRNA and DNA methylation 
and are characterized by their ability to influence 
gene expression without altering the DNA sequence 
in a stable and potentially heritable manner.
Epigenetic mechanisms
Perhaps the most complex of the three, histone 
proteins can be subjected to various posttransla-
tional modifications including acetylation, methyl-
ation, phosphorylation, ubiquitination, deimina-
tion and sumoylation. They are usually restricted 
to lysine and arginine residues but can also occur 
on serine and threonine. High levels of acetylation 
and trimethylated lysine (K) residue 4 of histone 
H3 (H3K4), H3K36 and H3K79 are associated with a 
more relaxed actively transcribed conformation of 
chromatin called euchromatin. Low levels of 
acetylation and high levels of H3K9, H3K27 and 
H4K20 methylation on the other hand result in a 
more condensed transcriptionally inactive hetero-
chromatin. Most posttranslational histone modifi-
cations are dynamic and are regulated by families 
of enzymes that either bind or remove specific 
functional groups. For example, histone acetyl-
transferases (HATs) add, while histone deacetylases 
(HDACs) remove acetylation marks. Histone meth-
yltransferases add methyl groups to arginine and 
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lysine residues, while deiminases and lysine 
demethylases reverse these changes. There is also 
a similar relationship between histone kinases and 
phosphatases (20,21).
miRNAs perform their regulatory role in a very dif-
ferent way. They are small, approximately 21 nu-
cleotide-long, non-coding RNAs usually associated 
with target gene repression. They facilitate bind-
ing of the RNA-induced silencing complex (RISC) 
to the target mRNA, usually within its 3´ UTR re-
gion. When miRNA sequence completely matches 
that of the target, mRNA is degraded. More often, 
miRNAs bind imperfectly to their targets, resulting 
in translational inhibition without mRNA cleavage. 
This can result in decreased target protein levels 
without any changes in the mRNA concentration. 
Individual miRNAs generally regulate multiple tar-
get genes at modest levels and many different 
miRNAs can target the same transcript (22).
Similar to miRNA-mediated posttranscriptional 
regulation, DNA methylation is mainly associated 
with gene repression. It is a reversible covalent 
binding of a single methyl group to the 5´ carbon 
of a cytosine residue located next to a guanosine. 
These dinucleotides commonly annotated as 
CpGs, occur with higher than expected frequency 
in regions referred to as CpG islands. These are un-
evenly distributed throughout the genome, locat-
ed in promoter regions of genes, within genes and 
in intergenic locations. DNA methylation patterns 
are established by three DNA methyltransferases 
(DNMTs), namely DNMT1, DNMT3A and DNMT3B, 
and can be preserved during DNA replication and 
mitosis. This enables the inheritance of DNA meth-
ylation-mediated repression of target gene ex-
pression. The mechanisms of DNA demethylation 
which can be either passive or active are not yet 
fully elucidated (20).
Coregulators of estrogen signaling
As already mentioned, recruitment of a variety of 
coregulators in large multifunctional protein com-
plexes is intrinsic to estrogen signaling. Most of 
these coregulators interact with many members of 
the nuclear receptor superfamily and are involved 
in chromatin remodeling, histone modifications, 
transcription initiation and elongation, splicing 
and proteasomal degradation. In addition to gene 
activation through coactivator recruitment, estro-
gen signaling is also associated with repression of 
transcription assisted by corepressors (12,13). Coac-
tivators associated with estrogen-mediated tran-
scription include v-src avian sarcoma (Schmidt-
Ruppin A-2) viral oncogene homolog (SRC1), nu-
clear receptor coactivator 2 (NCOA2), NCOA3, pro-
line, glutamate and leucine rich protein 1 (PELP1), 
CREB binding protein (CBP), E1A binding protein 
p300 (p300), K(lysine) acetyltransferase 2B (PCAF/
KAT2B), coactivator-associated arginine methyl-
transferase 1 (CARM1) and protein arginine meth-
yltransferase 1 (PRMT1) while estrogen-induced 
repression recruits corepressors nuclear receptor 
corepressor 1 (NCOR1), NCOR2 and metastasis as-
sociated 1 (MTA1) among others (23). Even though 
coregulators are involved in a multitude of tran-
scriptional steps we would like to point out their 
role as intermediates between transcriptional 
coregulation and epigenetic changes. A number 
of coregulators possess chromatin-modifying ac-
tivities such as acetyltransferase and methyltrans-
ferase activity. In fact, histone acetylation is a nec-
essary early step in transcription initiation marking 
active chromatin sites. Acetylation, as well as cer-
tain methylation marks attract additional tran-
scriptional coactivators which in turn recruit gen-
eral transcriptional machinery, including RNA 
polymerase and its accessory factors. The most 
commonly utilized HATs include p300, CBP, PCAF, 
KAT2A and KAT5. Conversely, removal of these 
acetylation marks from histones by corepressor 
complexes is associated with target gene silenc-
ing. Common HDACs include sirtuin 1 (SIRT1) and 
HDAC1-4 (24). Clearly chromatin modifications are 
integral to estrogen-mediated transcriptional reg-
ulation and gene expression in general.
Epigenetic regulation of estrogen signaling
Another contact point between estrogen signal-
ing and epigenetic mechanisms is the epigenetic 
control of ER gene expression. Through the regu-
lation of ER levels the epigenetic control extends 
to all ER target genes and estrogen-regulated 
processes. Several studies have shown that his-
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tone-modifying enzymes like, e.g. histone deacety-
lases HDAC1 and HDAC3 and histone methyltrans-
ferase suppressor of variegation 3-9 homolog 1 
(Drosophila) (SUV39H1), are at least in part respon-
sible for the reduction of ERα expression in onco-
logical settings, specifically in breast cancer (25-
29). Conversely, histone deacetylase SIRT1 activity 
is necessary for ERα expression in breast cancer. 
However, it was shown that SIRT1 is not directly as-
sociated with the ERα promoter and does not par-
ticipate in histone modifications but is rather in-
volved in the formation of basal transcription fac-
tor complexes at the ERα promoter. In addition, 
ERα and SIRT1 proteins directly interact to form 
transcriptional activator or repressor complexes 
depending on the targeted gene. This indicates 
that SIRT1 has other regulatory roles in addition to 
histone deacetylation (29,30). The balance be-
tween HATs and HDACs present at ERα gene pro-
moter was also pointed out as an important deter-
minant of gene expression and repression. Fur-
thermore, it was suggested that histone-modify-
ing enzymes establish a more transient gene re-
pression followed by the recruitment of DNMTs to 
the same regulatory complexes in order to meth-
ylate DNA for long-term gene silencing (26,31). De-
spite the lack of data on direct associations be-
tween different histone modifications and ERβ 
gene expression, several studies reported re-ex-
pression of ERβ after treatment with trichostatin A 
(TSA), an HDAC inhibitor, in breast, ovarian and 
prostate cancer cell lines. This effect was further 
increased when a DNMT inhibitor, 5-aza-2’-deoxy-
cytidine (5-AZA), was added to the TSA treatment 
(32-35). This supports the observed complementa-
ry roles of histone deacetylation and DNA methyl-
ation in repressing gene expression. An increase in 
ERβ expression was also observed in a non-onco-
logical setting after exposure to sodium butyrate, 
another HDAC inhibitor (36).
Similarly, miRNAs were also identified as important 
regulators of ER gene expression. ERα was shown 
to be directly targeted by numerous miRNAs, in-
cluding miR-18a, miR-22, and miR-206 (for a more 
comprehensive list see Table 3) (37-45). There is 
markedly less information available about miRNAs 
targeting ERβ and GPER1. So far only miR-92 was 
identified as a miRNA that directly targets ERβ, while 
no such miRNAs are known for GPER1 (22, 46).
DNA methylation is probably the most thoroughly 
analyzed epigenetic mechanism responsible for 
ER silencing in numerous malignancies. As already 
indicated, expression of several ERα and ERβ iso-
forms was shown to be inversely correlated with 
the methylation of CpGs at their respective pro-
moters. This association was observed repeatedly 
in multiple cell lines, primary cell cultures and tis-
sue samples of hematopoietic neoplasms, en-
dometrial, prostate, breast, and ovarian cancers, 
among others (47-53).
Even though the described studies focused mainly 
on epigenetic changes that resulted in ER silenc-
ing in numerous malignancies, they prove beyond 
a reasonable doubt that epigenetic mechanisms 
play an important role in the regulation of ER ex-
pression and consequently in the regulation of es-
trogen signaling.
Estrogen-mediated control of epigenetic 
mechanisms
The classic view of estrogen receptors as transcrip-
tion factors suggests that the roles of estrogen sig-


















miRNA – microRNA; ER – estrogen receptor.
Table 3. Experimentally validated miRNAs that directly regu-
late ER gene expression.
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naling and epigenetic regulation can also be re-
versed, meaning that estrogen signaling is also 
able to regulate expression of certain chromatin-
modifying enzymes and miRNAs (54).
An in vivo study showed a stimulatory effect of es-
trogen replacement on SIRT1 protein levels in 
bone marrow of estrogen-deficient mice (55). Acti-
vation of SIRT1 transcription by 17β-estradiol 
through ERα was also shown in breast cancer cell 
lines (29). Similarly, HDAC6 expression is also posi-
tively regulated by estrogen signaling (56). Fur-
thermore, a transcriptome profiling study in prima-
ry osteoblasts identified lysine (K)-specific methyl-
transferase 2D (MLL2) as an estrogen-responsive 
gene (57). These examples clearly show that estro-
gen signaling plays an important role in the regu-
lation of certain histone-modifying enzymes.
17β-estradiol also significantly upregulates and 
downregulates expression of numerous miRNAs. 
All three ERs were shown to directly and indirectly 
influence transcription of miRNAs in tumorous and 
normal cells. ERα-mediated estrogen signaling in-
hibits transcription of miR-21, miR-26a, miR-140, 
miR-181b and miR-206, while it stimulates expres-
sion of miR-190a, miR-191, miR-203 and miR-425 
among others (37,58-63). ERβ is on the other hand 
associated with downregulation of miR-17, miR-
30a, miR-200a and miR-200b, and upregulation of 
miR-23b, miR-24-1 and miR-27b among others (64, 
65). Additionally, binding of 17β-estradiol specifi-
cally to GPER1 was shown to repress the expres-
sion of miR-338-3p (66). A more comprehensive list 
of ER-regulated miRNAs is presented in Table 4.
As mentioned earlier, DNMTs are responsible for 
maintenance and de novo methylation of DNA. Es-
trogen signaling was clearly shown to influence 
the expression of DNMTs, although the results are 
quite diverse. DNMT1 was shown to be either 
downregulated or unaffected by 17β-estradiol, 
DNMT3A was downregulated, upregulated or un-
affected in the same conditions, while DNMT3B 
could be downregulated or upregulated. There are 
many potential explanations for this discordance, 
the most obvious being differences between vari-
ous malignant and non-malignant cell lines used 
by researchers, differences in their ER levels and 
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differences in the signaling coregulators present 
(14,67-72). In line with this, studies observed that 
estrogen signaling either increased DNA methyla-
tion and subsequently epigenetically silenced tar-
get genes or predominantly demethylated DNA 
resulting in epigenetic upregulation of down-
stream targets (31,67,68,73). Furthermore, develop-
mental exposure to relevant doses of 17β-estradiol 
or xenoestrogens induced hypomethylation of 
certain and hypermethylation of other genes, in-
creasing the susceptibility to certain types of adult-
onset cancer (72,74,75).
Estrogen signaling end epigenetic regulation are 
two ubiquitous regulatory mechanisms essential 
for maintaining cell and tissue homeostasis. Due 
to their importance it is not surprising that their 
functions tightly intertwine. In addition, their com-
plementary roles increase the level of cell-specifi-
city and fine-tuning of transcriptional regulation.
Conclusions
In the last two decades, we saw a dramatic in-
crease in our understanding of estrogen signaling. 
Extragonadal synthesis of estrogens and their tight 
connection with androgens have extended the 
mechanism of estrogen action from endocrine to 
paracrine, autocrine and even intracrine signaling. 
Estrogens and androgens have lost their gender-
limited roles importantly contributing to the phys-
iology of several tissues and organ systems. Fur-
thermore, at least three different estrogen recep-
tors, namely ERα, ERβ and GPER1, with distinct, 
non-redundant and in certain cases opposite roles 
are now known. Indirect genomic signaling 
through the interactions with other transcription 
factors at their DNA response elements and the 
fast non-genomic signaling mediated by mem-
brane-bound ERs additionally increase the com-
plexity of estrogen signaling. Importantly, estro-
gen signaling is also tightly connected to epige-
netic mechanisms both as the regulator of gene 
expression of certain chromatin-modifying en-
zymes and miRNAs, as well as their target through 
the epigenetic regulation of ER gene expression 
levels. Moreover, certain epigenetic changes are 
intrinsic to estrogen-mediated transcriptional reg-
ulation and are executed at least in part by coreg-
ulators of estrogen signaling. Epigenetic mecha-
nisms thus augment not only the intricacy but also 
the specificity and fine-tuning of estrogen-medi-
ated transcriptional control. Better comprehension 
of the complexity of estrogen regulation has deep-
ened our understanding of the effects of the exist-
ing estrogen receptor modulators as well as 
opened opportunities for the discovery of new tis-
sue- and perhaps even cell-specific compounds.
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Only miRNAs that where validated and thoroughly studied in 
individual references are included in the list.
ER – estrogen receptor; miRNA – microRNA; GPER1 – G 
protein-coupled estrogen receptor 1.
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